Market research
CIPLA.NSE Cipla Limited
NSE INR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1T
- P/E ratio
- 34.36
- Analyst target
- 1509.0834
- Dividend yield
- 0.0%
- Beta
- 0.09
Profile
Company facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE059A01026
- Market cap
- 1T
- P/E ratio
- 34.36
- Analyst target
- 1509.0834
- Dividend yield
- 0.0%
- Beta
- 0.09
About
About Cipla Limited
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney disorders, alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CIPLA.NSE discussion.
5 years, 5 months ago
Cipla Limited is currently in a long term uptrend where the price is trading 14.9% above its 200 day moving average.
From a valuation standpoint, the stock is 26.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.5.
Cipla Limited's total revenue rose by 18.2% to $52B since the same quarter in the previous year.
Its net income has increased by 113.1% to $7B since the same quarter in the previous year.
Finally, its free cash flow grew by 8.8% to $16B since the same quarter in the previous year.
Based on the above factors, Cipla Limited gets an overall score of 5/5.